[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![Quantumup1 Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1060595604022280192.png) quantumup [@Quantumup1](/creator/twitter/Quantumup1) on x 3533 followers
Created: 2025-07-24 13:20:24 UTC

H.C. Wainwright reiterated $VKTX Buy-$102 after Viking announced 2Q25 financial results said, "We continue to believe VK2735 is well-positioned within the GLP-1 landscape, across both subcutaneous and oral formulations."
$GPCR $LLY $NVO $TERN $AMGN $SRRK
Cantor reiterated $VKTX Overweight-$104 and said, "Viking announced 2Q25 earnings and while the company did not narrow timing of Phase X data for oral VK2735 (still 2H25), our understanding is it is simply because they do not have visibility on cleaning and ultimately timing of receipt of data from CRO. Viking has every incentive to announce these data as soon as they are available given it will inform dosing decisions for the Phase X maintenance study planned to start in 3Q25."


XXXXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1948372696837890273/c:line.svg)

**Related Topics**
[$alt](/topic/$alt)
[$tern](/topic/$tern)
[$lly](/topic/$lly)
[$gpcr](/topic/$gpcr)
[hc](/topic/hc)
[$vktx](/topic/$vktx)
[$vik](/topic/$vik)
[eli lilly](/topic/eli-lilly)

[Post Link](https://x.com/Quantumup1/status/1948372696837890273)